Transporter-mediated drug–drug interactions: advancement in models, analytical tools, and regulatory perspective

Abstract

Drug–drug interactions mediated by transporters are a serious clinical concern hence a tremendous amount of work has been done on the characterization of the transporter-mediated proteins in humans and animals. The underlying mechanism for the transporter-mediated drug–drug interaction is the induction or inhibition of the transporter which is involved in the cellular uptake and efflux of drugs. Transporter of the brain, liver, kidney, and intestine are major determinants that alter the absorption, distribution, metabolism, excretion profile of drugs, and considerably influence the pharmacokinetic profile of drugs. As a consequence, transporter proteins may affect the therapeutic activity and safety of drugs. However, mounting evidence suggests that many drugs change the activity and/or expression of the transporter protein. Accordingly, evaluation of drug interaction during the drug development process is an integral part of risk assessment and regulatory requirements. Therefore, this review will highlight the clinical significance of the transporter, their role in disease, possible cause underlying the drug–drug interactions using analytical tools, and update on the regulatory requirement. The recent in-silico approaches which emphasize the advancement in the discovery of drug–drug interactions are also highlighted in this review. Besides, we discuss several endogenous biomarkers that have shown to act as substrates for many transporters, which could be potent determinants to find the drug–drug interactions mediated by transporters. Transporter-mediated drug–drug interactions are taken into consideration in the drug approval process therefore we also provided the extrapolated decision trees from in-vitro to in-vivo, which may trigger the follow-up to clinical studies.

Keywords:

• Transporters
• drug–drug interactions
• analytical tools
• models
• biomarkers
• regulatory

Disclosure statement

The authors declare that there are no conflicts of interest.

Additional information

Funding

The present work was financially supported by the National Mission on Himalayan Studies (NMHS) (File No: GBPI/NMHS-2017-18/HSF-02), Ministry of Environment, Forest and Climate Change, Government of India andDepartment of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India.